The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts

Abstract

Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Despite their therapeutic potential, the use of ADCs faces significant challenges, including off/on-target toxicity and resistance development. This review examines the current landscape of ADC development, focusing on the critical aspects of target selection and antibody engineering. We discuss strategies to increase ADC efficacy and safety, including multitarget approaches, pH-dependent antibodies, and masked peptide technologies. The importance of comprehensive antigen expression profiling in both tumor and normal tissues is emphasized, highlighting the role of advanced technologies, such as single-cell sequencing and artificial intelligence, in optimizing target selection. Furthermore, we explore combination therapies and innovations in linker‒payload chemistry, which may provide approaches for expanding the therapeutic window of ADCs. These advances pave the way for the development of more precise and effective cancer treatments, potentially extending ADC applications beyond oncology.

Keywords

antibody-drug conjugates / target selection / normal and tumor tissue / off-target toxicity / response strategies

References

[1] Abu Al Karsaneh O, Al Anber A, M AL et al. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients. Diagn Pathol 2023;18:75.

[2] Abuhelwa Z, Alloghbi A, Alqahtani A et al. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs 2022;82:979–987.

[3] Ahmadi SE, Shabannezhad A, Kahrizi A et al. Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer. Biomarker Res 2023;11:60.

[4] Alrhmoun S, Sennikov S. The role of tumor-associated antigen HER2/neu in tumor development and the different approaches for using it in treatment: many choices and future directions. Cancers 2022;14:6173.

[5] Ambrosi C, Scribano D, Sarshar M et al. Acinetobacter baumannii targets human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) for Invasion of pneumocytes. mSystems 2020;5:e00604–e00620.

[6] Amisha F, Malik P, Saluja P et al. A comprehensive review on the role of human epidermal growth factor receptor 2 (HER2) as a biomarker in extra-mammary and extra-gastric cancers. Onco 2023;3:96–124.

[7] Bahrami A, Shahidsales S, Khazaei M et al. C-Met as a potential target for the treatment of gastrointestinal cancer: current status and future perspectives. J Cell Physiol 2017;232:2657–2673.

[8] Barve MA, Tine BAV, Redman RA et al. MT-6402, an engineered toxin body (ETB) targeting PD-L1: interim efficacy and safety data. J Clin Oncol 2023;41:2552–2552.

[9] Beck A, Goetsch L, Dumontet C et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017;16:315–337.

[10] Belting M, Dorrell MI, Sandgren S et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502–509.

[11] Bouleftour W, Guillot A, Magne N. The anti-Nectin 4: a promising tumor cells target. A systematic review. Mol Cancer Ther 2022;21:493–501.

[12] Boustany LM, LaPorte SL, Wong L et al. A Probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity. Cancer Res 2022;82:4288–4298.

[13] Cao W, Xing H, Li Y et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res 2022;10:38.

[14] Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy. Eur J Pharmacol 2021;911:174516.

[15] Chomet M, Schreurs M, Nguyen M et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by (89)Zr-immuno-PET in xenograft bearing mice. Theranostics 2020;10:5815–5828.

[16] Cleary JM, Calvo E, Moreno V et al. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs 2020;38:1483–1494.

[17] Colombo R, Tarantino P, Rich JR et al. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov 2024;14:2089–2108.

[18] Darmadi D, Aminov Z, Hjazi A et al. Investigation of the regulation of EGF signaling by miRNAs, delving into the underlying mechanism and signaling pathways in cancer. Exp Cell Res 2024;442:114267.

[19] de Bono JS, Concin N, Hong DS et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol 2019;20:383–393.

[20] Decary S, Berne PF, Nicolazzi C et al. Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res 2020;26:6589–6599.

[21] Deeks ED. Polatuzumab vedotin: first global approval. Drugs 2019;79:1467–1475.

[22] Deeks, EJD. (2021). Disitamab Vedotin: First Approval. Drugs 81, 1929–1935.

[23] DeLucia DC, Cardillo TM, Ang L et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin Cancer Res 2021;27:759–774.

[24] Deng H, Shi H, Chen L et al. Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int 2019;19:106.

[25] Dimopoulos MA, Hungria VT, Radinoff A et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol 2023;10:e801–e812.

[26] Dindere ME, Tanca A, Rusu M et al. Intraoperative tumor detection using pafolacianine. Int J Mol Sci 2022;23:12842.

[27] Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087–1097.

[28] Dum D, Taherpour N, Menz A et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18, 563 tumors. Pathobiology 2022;89:245–258.

[29] Dumontet C, Reichert JM, Senter PD et al. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov 2023;22:641–661.

[30] Duraivelan K, Samanta D. Emerging roles of the nectin family of cell adhesion molecules in tumour-associated pathways. Biochim Biophys Acta Rev Cancer 2021;1876:188589.

[31] Endo Y, Mohan N, Dokmanovic M et al. Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. Antib Ther 2021;4:55–59.

[32] Feng H, Bi S, Sun S et al. Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature. Front Oncol 2024;14:1367140.

[33] Flynn P, Suryaprakash S, Grossman D et al. The antibody-drug conjugate landscape. Nat Rev Drug Discov 2024;23:577–578.

[34] Fu Z, Gao C, Xie J et al. Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer 2023;23:960.

[35] Galizia G, Lieto E, Orditura M et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007;31:1458–1468.

[36] Gilmore JC, Hoque MT, Dai W et al. Interaction between dolutegravir and folate transporters and receptor in human and rodent placenta. EBioMed 2022;75:103771.

[37] Gina Battaglia P. Claudin-18 emerges as a novel therapeutic target in GI malignancies. Oncology Live 2023;24:47.

[38] Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotar 2018;9:28989–29006.

[39] Gomes-da-Silva LC, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. Oncoimmunology 2020;9:1841393.

[40] Gonzalez T, Muminovic M, Nano O et al. Folate receptor alpha-a novel approach to cancer therapy. Int J Mol Sci 2024;25:1046.

[41] Guo Z, Ding Y, Wang M et al. Safety of trastuzumab deruxtecan: a meta-analysis and pharmacovigilance study. J Clin Pharm Ther 2022;47:1837–1844.

[42] Hacker C.. Fam-Trastuzumab Deruxtecan-Nxki (Enhertu^®). Oncology Time 2020;42:6.

[43] Hafeez U, Parakh S, Gan HK et al. Antibody-drug conjugates for cancer therapy. Molecules 2020;25:4764.

[44] Han ZW, Lyv ZW, Cui B et al. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs 2020;38:1888–1898.

[45] Hashimoto H, Tanaka Y, Murata M et al. Nectin-4: a novel therapeutic target for skin cancers. Curr Treat Options Oncol 2022;23:578–593.

[46] Hassan N, Efing J, Kiesel L et al. The tissue factor pathway in cancer: overview and role of heparan sulfate proteoglycans. Cancers 2023;15:1524.

[47] Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol 2021;18:93–103.

[48] Heidari Z, Naeimzadeh Y, Fallahi J et al. The role of tissue factor in signaling pathways of pathological conditions and angiogenesis. Curr Mol Med 2024;24:1135–1151.

[49] Heo YA. Mirvetuximab soravtansine: first approval. Drugs 2023;83:265–273.

[50] Hofheinz R, Lorenzen S, Bohlmann MK. HER-2-positive tumors: a continuously evolving field in cancer research. Cancers (Basel) 2023;15:3333.

[51] Horst E, Jiang Z-G, Malhotra K et al. SNS-101, a highly selective monoclonal antibody against the active form of VISTA, demonstrates significantly reduced cytokine release. J Clin Oncol 2022;40:e14504–e14504.

[52] Hsu C, Huang CL, Hsu HC et al. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 2002;94:415–420.

[53] Huang H, Wu T, Shi H et al. Modular design of nanobody-drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent. Chem Commun (Camb) 2019;55:5175–5178.

[54] Huang SC, Chang SC, Liao TT et al. Detection and clinical significance of CEACAM5 methylation in colorectal cancer patients. Cancer Sci 2024;115:270–282.

[55] Keam SJ. Trastuzumab deruxtecan: first approval. Drugs 2020;80:501–508.

[56] Kern K, Delaroque N, Boysen A et al. Glycosylation of bacterial antigens changes epitope patterns. Front Immunol 2023;14:1258136.

[57] Kim JH, Kim BJ, Kim HS. Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. Oncotar 2017;8:113120–113128.

[58] Kim Y-N, Chung YS, Park E et al. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer. Sci Rep 2024;14:7992.

[59] Kirkpatrick P. Billion-dollar bets on antibody–drug conjugates. Nature Biopharma Dealmakers 2024.

[60] Kobayashi H, Choyke PJI. Future applications of and prospects for near-IR photoimmunotherapy: benefits and differences compared with photodynamic and photothermal therapy. Immunotherapy 2021;13:1305–1307.

[61] Lassman AB, Pugh SL, Wang TJC et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol 2023;25:339–350.

[62] Liang Y, Zhang T, Zhang J. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: their relevance for cancer therapy. Pharmacol Res 2020;161:105164.

[63] Liu B, Diaz Arguello OA, Chen D et al. CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation. PLoS One 2020;15:e0232985.

[64] Liu Y, Han X, Li L et al. Role of Nectin-4 protein in cancer (Review). Int J Oncol 2021;59:93.

[65] Liu J, Yang H, Yin D et al. Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma. Pathol Res Pract 2022a;238:154068.

[66] Liu S, Yin S, Lyu W et al. Abstract 4263: a novel pegylated biparatopic antibody-drug conjugate (pb-adc) targeting cancers with low HER2+ expression. Cancer Res 2022b;82:4263.

[67] Liu X, Tian X, Hao X et al. A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Mol Ther Oncolytics 2022c;27:256–269.

[68] Lombardi P, Filetti M, Falcone R et al. Overview of trop-2 in cancer: from pre-clinical studies to future directions in clinical settings. Cancers 2023;15:1744.

[69] London M, Gallo E. Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. Cell Biol Int 2020;44:1267–1282.

[70] Luu K, Chu A, Chang B. A review of the novel tissue factor antibody-drug conjugate: tisotumab vedotin. J Oncol Pharm Pract 2023;29:441–449.

[71] Mai J, Wu L, Yang L et al. Therapeutic strategies targeting folate receptor α for ovarian cancer. Front Immunol 2023;14:1254532.

[72] Matulonis U, Lorusso D, Oaknin A et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study (LBA 4). Gynecol Oncol 2022;166:S50.

[73] Mei M, Thomas S, Chen R. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin. BioDrugs 2014;28:245–251.

[74] Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480–489.

[75] Miller DR. A tribute to Sidney Farber – the father of modern chemotherapy. Br J Haematol 2006;134:20–26.

[76] Mori S, Akita H, Kobayashi S et al. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Cancer Lett 2021;512:51–59.

[77] Nagayama A, Ellisen LW, Chabner B et al. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol 2017;12:719–739.

[78] Nair S, Bonner JA, Bredel M. EGFR Mutations in head and neck squamous cell carcinoma. Int J Mol Sci 2022;23:3818.

[79] Narayan P, Osgood CL, Singh H et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res 2021;27:4478–4485.

[80] Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers 2023;15:713.

[81] Norsworthy KJ, Ko CW, Lee JE et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist 2018;23:1103–1108.

[82] Norton N, Youssef B, Hillman DW et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer 2020;6:4.

[83] plc, G. Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma. GKS Media Press reseases. 2024.

[84] Ponziani S, Di Vittorio G, Pitari G et al. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci 2020;21:5510.

[85] Poon K, Flagella K, Beyer J et al. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 2013;273:298–313.

[86] Qiu S, Zhang J, Wang Z et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochim Biophys Acta Rev Cancer 2023;1878:188902.

[87] Radziejewska A, Chmurzynska A. Folate and choline absorption and uptake: Their role in fetal development. Biochimie 2019;158:10–19.

[88] Randall J, Hunt AL, Nutcharoen A et al. Quantitative proteomic analysis of HER2 protein expression in PDAC tumors. Clin Proteomics 2024;21:24.

[89] Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417–6427.

[90] Ricordel C, Barlesi F, Cousin S et al. Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). J Clin Oncol 2022;40:9039–9039.

[91] Rondon AMR, Kroone C, Kapteijn MY et al. Role of tissue factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2019;45:396–412.

[92] Rong Y, Hu F, Huang R et al. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res 2006;66:7067–7074.

[93] Rosenberg JE, O’Donnell PH, Balar AV et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37:2592–2600.

[94] Saikia T. The cure of chronic myeloid leukemia: are we there yet? Curr Oncol Rep 2018;20:12.

[95] Saito A, Nishikawa T, Yoshida H et al. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma. Gynecol Oncol 2023;176:115–121.

[96] Sakellakis M, Spathas N, Tsaousis KT et al. Potential ophthalmological side effects induced by anti-neoplastic regimens for the treatment of genitourinary cancers: a review. Cureus 2022;14:e27266.

[97] Sanborn RE, Hamid O, de Vries EG et al. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. J ImmunoTher Cancer 2021;9:e002446.

[98] Scaranti M, Cojocaru E, Banerjee S et al. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol 2020;17:349–359.

[99] Schlam I, Tarantino P, Tolaney SM. Managing adverse events of sacituzumab govitecan. Expert Opin Biol Ther 2023;23:1103–1111.

[100] Shen M, Liu S, Stoyanova T. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol 2021;9:73–87.

[101] Shi X, Xu P, Cao C et al. PET/NIR-II fluorescence imaging and image-guided surgery of glioblastoma using a folate receptor α-targeted dual-modal nanoprobe. Eur J Nucl Med Mol Imaging 2022;49:4325–4337.

[102] Shitara K, Baba E, Fujitani K et al. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer 2021;24:780–789.

[103] Singh P, Toom S, Huang YJ. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 2017;10:105.

[104] Slavcheva SE, Angelov A. HER2-targeted therapy-from pathophysiology to clinical manifestation: a narrative review. J Cardiovasc Dev Dis 2023;10:489.

[105] Subramaniyan V, Fuloria S, Gupta G et al. A review on epidermal growth factor receptor’s role in breast and non-small cell lung cancer. Chem Biol Interact 2022;351:109735.

[106] Tanaka Y, Murata M, Oda Y et al. Nectin cell adhesion molecule 4 (NECTIN4) expression in cutaneous squamous cell carcinoma: a new therapeutic target? Biomed 2021;9:355.

[107] Tanaka M, Miyazawa H, Terashima R et al. Conditional early approval for new drug applications in Japan: Current and emerging issues. Clin Transl Sci 2023;16:1289–1293.

[108] Tolcher A, Hamilton E, Coleman RL. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev 2023;116:102546.

[109] Unruh D, Horbinski C. Beyond thrombosis: the impact of tissue factor signaling in cancer. J Hematol Oncol 2020;13:93.

[110] Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers 2021;13:2748.

[111] Varaganti P, Buddolla V, Lakshmi BA et al. Recent advances in using folate receptor 1 (FOLR1) for cancer diagnosis and treatment, with an emphasis on cancers that affect women. Life Sci 2023;326:121802.

[112] Verma S, Breadner D, Raphael J. ‘Targeting’ improved outcomes with antibody-drug conjugates in nonsmall cell lung cancer-an updated review. Curr Oncol 2023;30:4329–4350.

[113] von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380:617–628.

[114] Wahby S, Fashoyin-Aje L, Osgood CL et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin Cancer Res 2021;27:1850–1854.

[115] Wang H, Liu C, Han J et al. HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue. Oncol Lett 2012;4:194–198.

[116] Wang C, Tran DA, Fu MZ et al. Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer. J Cancer 2020a;11:1693–1701.

[117] Wang H, Rao B, Lou J et al. The function of the HGF/c-Met Axis in hepatocellular carcinoma. Front Cell Dev Biol 2020b;8:55.

[118] Warren EAK, Anil J, Castro PD et al. Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: variation within and across primary tumor sites, and implications for antigen-specific immunotherapy. Head Neck 2021;43:1983–1994.

[119] Wei W, Sulea T. Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications. MAbs 2024;16:2404064.

[120] Wolber P, Nachtsheim L, Hoffmann F et al. Trophoblast cell surface antigen 2 (Trop-2) protein is highly expressed in salivary gland carcinomas and represents a potential therapeutic target. Head and Neck Pathology 2021;15:1147–1155.

[121] Wu Q, Bai B, Tian C et al. The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review. Cardiovasc Drugs Ther 2022a;36:511–524.

[122] Wu Y, Li Q, Kong Y et al. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther 2022b;30:2785–2799.

[123] Xu C, Du L, Zeng Z et al. Elevated CEACAM5 levels in patients with asthma. Int Arch Allergy Immunol 2022;183:673–681.

[124] Xu G, Liu W, Wang Y et al. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med 2024;5:101710.

[125] Yang X, Liao H-Y, Zhang H-H. Roles of MET in human cancer. Clinica Chimica acta; 2022;525:69–83.

[126] Ye W, Liu X, He R et al. Improving antibody affinity through in vitro mutagenesis in complementarity determining regions. J Biomed Res 2022;36:155–166.

[127] Zaman S, Jadid H, Denson AC et al. Targeting Trop-2 in solid tumors: future prospects. OncoTargets Ther 2019;12:1781–1790.

[128] Zhang Y, Chen P, Yin W et al. Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Hum Pathol 2018;72:107–116.

[129] Zhao Y, Ye W, Wang YD et al. HGF/c-Met: a key promoter in liver regeneration. Front Pharmacol 2022;13:808855.

[130] Zhou J, Fan X, Chen N et al. Identification of CEACAM5 as a Biomarker for Prewarning and Prognosis in Gastric Cancer. J Histochem Cytochem 2015;63:922–930.

[131] Zhu Y, Liu K, Wang K et al. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. Cancer 2023;129:283–295.

[132] Zhu XY, Li QX, Kong Y et al. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacol Sin 2024;45:609–618.

RIGHTS & PERMISSIONS

The Author(s) 2025. Published by Oxford University Press on behalf of Higher Education Press.